摘要
目的观察培关曲塞联合奈达铂治疗老年晚期非鳞型肺癌的疗效及不良反应。方法56例患者均接受培关曲塞＋奈达铂化疗，21d为1个周期。患者的近期疗效采用实体瘤的治疗效果评价标准评价。结果所有患者均完成2～6个周期化疗。56例患者中完全缓解9例（16．1％），部分缓解12例（21．4％），稳定19例（33．9％），进展16例（28．6％）；有效率为37．5％，临床受益率为71．4％（40／56）；患者6个月生存率及1年生存率分别为69．4％（39／56）、35．7％（20／56）。无药物相关性死亡事件发生，不良反应主要为血液学毒性和消化道毒性，偶有轻度肝、肾功能损害。结论培关曲塞联合奈达铂治疗有较好的有效性及安全性．不良反应可耐受。
Objective To observe the clinical efficacy of S-1 combined with pemetrexed on elderly patients with advanced non-squamous lung cancer. Methods Fifty-six patients were treated with pemetrexed ＋ nedaplatin chemotherapy, repeated once every 21 days, then the short-effect curative effect was evaluated by the standard of solid tumor. Results Among the 56 patients, CR in 9 cases（ 16.1% ） , PR in 12 cases（21.4% ）, SD in 19 cases（33.9% ）, PD in 16 cases（28.6% ） ; the effective rate was 37.5% , the clinical benefit rate was 71.4% , the six-month survival rate was 69.4% （39/56） and the one-year survival rate was 35.7% （20/56） ; No drug-related death happened. The main side effects were hematological toxicity and gastrointestinal toxicity, occasional mild hepatic dysfunction and impaired renal function. Conclusions S-1 combined with pemetrexed in the treatment of elderly patients with advanced non-squamous lung cancer has good efficacy and safety, the side effects are tolerable.
出处
《中国实用医刊》
2015年第5期16-17,共2页
Chinese Journal of Practical Medicine
关键词
老年非鳞型肺癌
培美曲塞
奈达铂
化疗
Elderly patients with advanced non-squamous lung cancer
Pemetrexed
S-1
Chemotherapy
